| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P2093 | author name string | Jie Yan | |
| Yan Jiang | |||
| Shu Zhang | |||
| Gang Zhang | |||
| Shuai Hao | |||
| Chunyan Hu | |||
| Bo Gao | |||
| Xiaohua Zhang | |||
| Donglin Luo | |||
| Lingji Guo | |||
| Wuguo Tian | |||
| Jianjie Zhao | |||
| P2860 | cites work | Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 |
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial | Q27851705 | ||
| Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study | Q27851763 | ||
| Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer | Q27853134 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? | Q29619328 | ||
| Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial | Q30758991 | ||
| Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer | Q33339971 | ||
| Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. | Q33827808 | ||
| Emerging targeted therapies for breast cancer | Q34119550 | ||
| Beta blockade during and after myocardial infarction: an overview of the randomized trials | Q34557544 | ||
| Cardiac toxicity in breast cancer patients treated with dual HER2 blockade | Q34694972 | ||
| Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study | Q35005762 | ||
| Risk of severe diarrhea with dual anti-HER2 therapies: a meta-analysis | Q35077315 | ||
| Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials | Q35345642 | ||
| Risk of mucocutaneous toxicities in patients with solid tumors treated with lapatinib: a systematic review and meta-analysis | Q35566551 | ||
| Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial | Q35576189 | ||
| Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006 | Q36810717 | ||
| Current approaches and future directions in the treatment of HER2-positive breast cancer | Q37330128 | ||
| The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine | Q37433324 | ||
| Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer | Q37626334 | ||
| Dual HER2-targeted approaches in HER2-positive breast cancer | Q37940203 | ||
| Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer | Q38046722 | ||
| Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS). | Q40218182 | ||
| Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. | Q40708568 | ||
| Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response | Q42677733 | ||
| Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study | Q46256397 | ||
| Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial | Q46764831 | ||
| Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial | Q47255118 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study | Q80574611 | ||
| Heterogeneity testing in meta-analysis of genome searches | Q81128804 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 19923-19933 | |
| P577 | publication date | 2017-02-10 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials | |
| P478 | volume | 8 |
| Q47375942 | Near-infrared remotely triggered drug-release strategies for cancer treatment | cites work | P2860 |
Search more.